137 related articles for article (PubMed ID: 27681847)
1. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.
N Kalimuthu S; Serra S; Dhani N; Hafezi-Bakhtiari S; Szentgyorgyi E; Vajpeyi R; Chetty R
J Clin Pathol; 2017 Mar; 70(3):237-243. PubMed ID: 27681847
[TBL] [Abstract][Full Text] [Related]
2. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
[TBL] [Abstract][Full Text] [Related]
3. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
[TBL] [Abstract][Full Text] [Related]
4. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
[TBL] [Abstract][Full Text] [Related]
5. Interobserver agreement and accuracy of preoperative endoscopic ultrasound-guided biopsy for histological grading of pancreatic cancer.
Larghi A; Correale L; Ricci R; Abdulkader I; Monges G; Iglesias-Garcia J; Giovannini M; Attili F; Vitale G; Hassan C; Costamagna G; Rindi G
Endoscopy; 2015 Apr; 47(4):308-14. PubMed ID: 25521572
[TBL] [Abstract][Full Text] [Related]
6. International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems.
Chetty R; Gill P; Govender D; Bateman A; Chang HJ; Deshpande V; Driman D; Gomez M; Greywoode G; Jaynes E; Lee CS; Locketz M; Rowsell C; Rullier A; Serra S; Shepherd N; Szentgyorgyi E; Vajpeyi R; Wang LM; Bateman A
Hum Pathol; 2012 Nov; 43(11):1917-23. PubMed ID: 22575264
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
Kim SS; Ko AH; Nakakura EK; Wang ZJ; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Kim GE
Am J Surg Pathol; 2019 Mar; 43(3):334-340. PubMed ID: 30211728
[TBL] [Abstract][Full Text] [Related]
8. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
[TBL] [Abstract][Full Text] [Related]
9. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications.
Nagaria TS; Wang H; Chatterjee D; Wang H
Arch Pathol Lab Med; 2020 Jul; 144(7):838-845. PubMed ID: 32023088
[TBL] [Abstract][Full Text] [Related]
10. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach.
Chou A; Ahadi M; Arena J; Sioson L; Sheen A; Fuchs TL; Pavlakis N; Clarke S; Kneebone A; Hruby G; Sahni S; Mittal A; Samra J; Gill AJ
Am J Surg Pathol; 2021 Mar; 45(3):394-404. PubMed ID: 33074853
[TBL] [Abstract][Full Text] [Related]
11. Grading epithelial atypia in endoscopic ultrasound-guided fine-needle aspiration of intraductal papillary mucinous neoplasms: an international interobserver concordance study.
Pitman MB; Centeno BA; Genevay M; Fonseca R; Mino-Kenudson M
Cancer Cytopathol; 2013 Dec; 121(12):729-36. PubMed ID: 23881863
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma.
Kameyama A; Ye J; Shimomura A; Yokohira M; Nakano-Narusawa Y; Yamakawa K; Mukai Y; Sanomura T; Okuyama H; Miyatake N; Furihata M; Tanaka C; Kitazawa R; Bando Y; Suemitsu Y; Kojima M; Mino-Kenudson M; Suzuki Y; Okano K; Matsuda Y
Pancreatology; 2021 Dec; 21(8):1506-1515. PubMed ID: 34563448
[TBL] [Abstract][Full Text] [Related]
13. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
14. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review.
van Roessel S; Janssen BV; Soer EC; Fariña Sarasqueta A; Verbeke CS; Luchini C; Brosens LAA; Verheij J; Besselink MG
Br J Surg; 2021 Mar; 108(2):119-127. PubMed ID: 33711148
[TBL] [Abstract][Full Text] [Related]
15. The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes.
Kalimuthu SN; Serra S; Dhani N; Chetty R
J Clin Pathol; 2016 Jun; 69(6):463-71. PubMed ID: 26915370
[TBL] [Abstract][Full Text] [Related]
16. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes.
Zhang ML; Kem M; Rodrigues C; Sandini M; Ciprani D; Hank T; Kunitoki K; Qadan M; Ferrone C; Lillemoe K; Fernández-Del Castillo C; Mino-Kenudson M
Histopathology; 2020 Jul; 77(1):144-155. PubMed ID: 31965618
[TBL] [Abstract][Full Text] [Related]
17. Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications.
Cacciato Insilla A; Vivaldi C; Giordano M; Vasile E; Cappelli C; Kauffmann E; Napoli N; Falcone A; Boggi U; Campani D
Front Oncol; 2020; 10():64. PubMed ID: 32117724
[TBL] [Abstract][Full Text] [Related]
18. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma.
Haeberle L; Cacciato Insilla A; Kapp AC; Steiger K; Schlitter AM; Konukiewitz B; Demir IE; Friess H; Esposito I
Histol Histopathol; 2021 Jul; 36(7):733-742. PubMed ID: 33769550
[TBL] [Abstract][Full Text] [Related]
19. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
[TBL] [Abstract][Full Text] [Related]
20. Pathological assessment of tumour regression following neoadjuvant therapy in pancreatic carcinoma.
Hemmings C; Connor S
Pathology; 2020 Oct; 52(6):621-626. PubMed ID: 32800331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
